As of Mar 22
| +0.60 / +4.92%|
The 8 analysts offering 12-month price forecasts for Cytokinetics Inc have a median target of 21.50, with a high estimate of 25.00 and a low estimate of 15.00. The median estimate represents a +67.97% increase from the last price of 12.80.
The current consensus among 7 polled investment analysts is to Buy stock in Cytokinetics Inc. This rating has held steady since March, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.